Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genta restructures operations to focus on oncology development
In March 2008, the company has received notice that its appeal of an adverse decision by the FDA’s Center for Drug Evaluation and Research (CDER) regarding its new
In March 2008, the company has received notice that its appeal of an adverse decision by the FDA’s Center for Drug Evaluation and Research (CDER) regarding its new
Under the agreement, Kelun Medicine will guarantee to distribute $2.78 million (RMB20 million) worth of Tianyin products within Sichuan Province between April 1, 2008 and March 31, 2009.
According to the consumer group, the drugs – used in the treatment of gastroesophageal disorders, blood pressure and arthritis, plus anticoagulants and antiplatelet agents for use in prevention
Philip Morris gave grants to scientists at Boston University, Harvard University, the Massachusetts Institute of Technology, and the University of Massachusetts. The company also revealed that it has
A survey conducted by the association found that 400 out of the 650 patients who switched to another pain medication experienced a decline in their health. And about
Moleac will use this injection of funds to market its first product NeuroAid on a global scale. Moleac will also use the investments to fund international clinical trials
ITMN-191 was administered as monotherapy in patients with chronic hepatitis C virus (HCV) genotype 1 infection. InterMune reported that treatment with ITMN-191 resulted in rapid and significant reductions
With CE Marking approval NeoVista now has the ability to distribute and sell its product throughout all EU countries, offering a new treatment option for two million Europeans
Compugen also received a patent for this biomarker from the US Patent and Trademark Office. Under the recently signed agreement with Biosite, Compugen will provide Biosite with all
The eight-month angiographic follow-up continued to demonstrate reduction in late lumen loss and neointimal hyperplasia formation. In-stent late lumen loss was 0.31 ± 0.25 mm, neointimal volume obstruction